In Vivo Measurements of Fibrin Formation and Fibrinolysis in Operable Breast Cancer

Summary

Fibrin formation and fibrinolysis were estimated in 89 breast cancer patients by measurement in plasma of Fibrin Fragment Bβ 15-42 and Fibrinopeptide A (FPA), serum Fibrin(ogen) Degradation Products (FDPs) and plasminogen activator by Fibrin Plate Lysis Assay. Results were compared with (a) 26 patients with benign breast diseases; and (b) 45 healthy factory workers. FPA, FDP and Bβ 15-42 Levels were elevated in both breast cancer patients and benign disease patients, but there were no significant differences between these two groups. Cancer stage, patient age and smoking habits did not affect these results, but Oestrogen Receptor (ER) positive patients had higher Bβ 15-42 values than ER negative patients (p = 0.017). These results show that fibrin formation is enhanced preoperatively in patients with either benign or malignant breast disease. The fibrinolytic response to activated coagulation may be relatively deficient in breast cancer. The roles of malignancy, stress and other factors in the causation of these abnormalities require further assessment.

Keywords

Breast cancer - Haemostasis - Fragment Bβ 15-42 - Fibrinopeptide A

• References

• 1 Slichter SJ, Harker LA. Haemostasis in malignancy. Ann NY Acad Sci 1974; 230: 252-261
• 2 Sun MC J, McAfee WM, Hum GJ. et al Haemostatic abnormalities in malignancy: a prospective study of 108 patients. Am J Clin Pathol 1979; 71: 10-16
• 3 Mannucci PM, Vaglini M, Maniezzo M. et al Haemostatic alterations are unrelated to stage of tumour in untreated malignant melanoma and breast cancer. Eur J Cancer Clin Oncol 1985; 21: 681-685
• 4 Agostino D, Cliffton EE, Girolami A. Effect of prolonged coumadin treatment on the production of pulmonary metastases in the rat. Cancer 1966; 19: 284-288
• 5 Poggi A, Donati MM, Garattini S. Fibrin and cancer cell growth. Problems in the evaluation of experimental models In: Donati MB, Davidson JF, Garattini S. (eds) Malignancy and the Haemostatic System. Raven; New York: 1981. pp 89-101
• 6 McCulloch PG, George WD. Warfarin inhibition of metastasis; the role of anticoagulation. Br J Surg 1987; 74: 879-883
• 7 Nossel HL, Younger L, Wilner GD. et al Radioimmunoassay of human fibrinopeptide A. Proc Natl Acad Sci (USA) 1971; 68: 2350-2353
• 8 Kudryk B, Robinson D, Netre C. et al Measurement in human blood of fibrinogen/fibrin fragments containing the B-beta 15-42 sequence. Thromb Res 1982; 25: 277-291
• 9 Peuscher FW, Cleton FJ, Armstrong L, Stoepman-Van Dalen EE, Van Mourik JA, Van Aken WG. Significance of plasma fibrinopeptide A (FPA) in patients with malignancy. J Lab Clin Med 1980; 96: 5-14
• 10 Rickies FR, Edwards RL, Barb C, Cronlund M. Abnormalities of coagulation in cancer. Cancer 1983; 51: 301-307
• 11 Auger MJ, Galloway MJ, Leinster SJ, McVerry BA, Mackie MJ. Elevated Fibrinopeptide A levels in patients with clinically localised breast carcinoma. Haemostasis 1987; 17: 336-339
• 12 Green B, Leake RE. Steroid Hormones: A Practical Approach. IRL press; Oxford: 1987. p 82
• 13 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
• 14 Merskey C, Lalezari P, Johnson AJ. A rapid, simple sensitive method for measuring fibrinolytic split products in human serum. Proc Soc Exp Biol Med 1969; 131: 871-875
• 15 Kluft C, Brakman P, Velduyzen-Stolk EP. Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Davidson JF, Samama MM, Desnoyers PC. (eds) Progress in Chemical Fibrinolysis and Thrombolysis. Vol.2. Raven; New York: 1976. pp 57-65
• 16 Imaoka S, Sasaki Y, Iwanaga T, Terasawa T. The significance of the fibrinogen/fibrin degradation product in serum of carcinoma patients with haematogenous metastasis. Cancer 1986; 58: 1488-1492
• 17 Nossel HL. Relative proteolysis of the fibrinogen Bp chain by thrombin and by plasmin as a determinant of thrombosis. Nature 1981; 291 (5811) 165-167
• 18 Hagedom AB, Bowie EJ, Elveback LR, Owen CA. Coagulation abnormalities in patients with inoperable lung carcinoma. Mayo Clinic Proc 1974; 49: 647-653
• 19 Rennie JA N, Ogston D. Fibrinolytic activity in malignant disease. J Clin Pathol 1975; 28: 872-874
• 20 Reeve EB, Franks JJ. Fibrinogen synthesis, distribution and degradation. Semin Thromb Haemostas 1974; 1: 129-183
• 21 Davis RP, Theologides A, Kennedy BJ. Comparative study of blood coagulation changes in patients with cancer and with non-malignant diseases. Ann Intern Med 1969; 71: 67-80
• 22 Lowe GD O, Small M. Stimulation of endogenous fibrinolysis. In: Kluft C. (ed) Tissue-type Plasminogen Activator (TPA). CRC Press; Boca Raton, FL: 1988. (in press)
• 23 Crawford R, Scrutton MC. Biochemistry of the blood platelet. In: Bloom AL, Thomas DP. (eds) Haemostasis and Thrombosis. 2. Churchill Livingstone; Edinburgh: 1987